Xenetic Biosciences — Third Quarter 2026 Earnings Summary

Xenetic Biosciences reported a net loss of approximately $1.7 million for the third quarter of 2026, driven by a 138% increase in general and administrative expenses related to a proposed share exchange transaction. The company entered into a definitive agreement to acquire Santersus AG in an all-stock deal expected to close in early 2027, creating a Nasdaq-listed entity named Santersus Bio, Inc. focused on targeting neutrophil extracellular traps across multiple therapeutic areas. Strategic highlights include the initiation of a Phase I clinical study combining Xenetic's DNase I technology with CAR T-cell therapy for large B-cell lymphoma and the advancement of preclinical research demonstrating DNase I's ability to enhance antitumor activity.